Compagnie Lombard Odier SCmA Decreases Stock Position in Incyte Corporation $INCY

Compagnie Lombard Odier SCmA cut its stake in Incyte Corporation (NASDAQ:INCY) by 94.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,120 shares of the biopharmaceutical company’s stock after selling 21,030 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in Incyte were worth $95,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. denkapparat Operations GmbH raised its position in Incyte by 46.1% in the 2nd quarter. denkapparat Operations GmbH now owns 11,292 shares of the biopharmaceutical company’s stock worth $769,000 after purchasing an additional 3,564 shares during the period. LBP AM SA grew its stake in shares of Incyte by 33.6% during the third quarter. LBP AM SA now owns 238,705 shares of the biopharmaceutical company’s stock valued at $20,245,000 after buying an additional 59,974 shares during the last quarter. Rakuten Investment Management Inc. purchased a new stake in shares of Incyte in the third quarter worth approximately $14,646,000. Massachusetts Financial Services Co. MA lifted its stake in shares of Incyte by 38.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 387,605 shares of the biopharmaceutical company’s stock worth $32,873,000 after acquiring an additional 108,645 shares during the last quarter. Finally, Callan Family Office LLC bought a new stake in shares of Incyte during the 2nd quarter worth approximately $636,000. Institutional investors own 96.97% of the company’s stock.

Incyte Trading Down 8.2%

NASDAQ:INCY opened at $100.05 on Wednesday. The firm has a 50-day simple moving average of $101.80 and a 200-day simple moving average of $93.78. Incyte Corporation has a one year low of $53.56 and a one year high of $112.29. The firm has a market cap of $19.64 billion, a P/E ratio of 16.76, a P/E/G ratio of 0.65 and a beta of 0.82. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.13 and a current ratio of 3.20.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The business had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.35 billion. Incyte had a net margin of 24.69% and a return on equity of 26.56%. Incyte’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.43 earnings per share. Equities analysts anticipate that Incyte Corporation will post 4.86 EPS for the current fiscal year.

Analysts Set New Price Targets

INCY has been the topic of several research analyst reports. Barclays upped their price objective on Incyte from $115.00 to $116.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $90.00 price target on shares of Incyte in a research note on Thursday, January 8th. Royal Bank Of Canada lifted their price objective on shares of Incyte from $81.00 to $84.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Piper Sandler upped their target price on shares of Incyte from $102.00 to $110.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Guggenheim raised shares of Incyte from a “neutral” rating to a “buy” rating and set a $125.00 target price on the stock in a research report on Monday, November 3rd. Nine research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Incyte has a consensus rating of “Hold” and an average target price of $103.29.

Incyte News Summary

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Revenue and product sales beat estimates — Q4 revenue rose ~28%, driven by Jakafi and Opzelura strength, which supports near‑term cash flow and validates commercial execution. INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
• Positive Sentiment: Management emphasized growth beyond Jakafi and pipeline progress on the earnings call, signaling strategic intent to diversify revenue sources over time. Incyte Earnings Call Highlights Growth Beyond Jakafi
• Neutral Sentiment: Full earnings/earnings call transcripts and slide deck are now public for investor review (details on metrics, guidance assumptions). Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Coverage and index mentions (Nasdaq Composite commentary) have increased visibility but are unlikely to move fundamentals immediately. Why Incyte (NASDAQ:INCY) Appears in Nasdaq Composite Index Coverage?
• Neutral Sentiment: Reported short‑interest data in the clip is inconsistent/zero and provides no clear signal about short pressure this filing window.
• Negative Sentiment: EPS missed consensus ($1.80 vs. ~$1.96) — investors focus on the profit miss even though revenue was strong, pressuring the multiple. Incyte (INCY) Q4 Earnings Lag Estimates
• Negative Sentiment: Management issued a soft 2026 revenue forecast and lower Opzelura guidance, heightening concern about whether new products can offset Jakafi patent expirations; analysts flagged increased risk to future sales. Incyte weak 2026 revenue forecast heightens Jakafi patent concerns
• Negative Sentiment: Market reaction: multiple outlets report the stock fell after the EPS miss and soft guidance — the headline price action reflects disappointment that growth drivers may not fully offset Jakafi risks. Incyte falls as Q4 results, 2026 revenue guidance disappoint

Insider Buying and Selling

In other news, EVP Michael James Morrissey sold 54,008 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $97.29, for a total value of $5,254,438.32. Following the completion of the transaction, the executive vice president directly owned 31,830 shares of the company’s stock, valued at approximately $3,096,740.70. The trade was a 62.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Thomas Tray sold 2,774 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $100.00, for a total value of $277,400.00. Following the sale, the insider directly owned 22,973 shares in the company, valued at approximately $2,297,300. The trade was a 10.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 95,225 shares of company stock valued at $9,519,745. 17.80% of the stock is owned by insiders.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.